

CNIO Frontiers Meetings

Breast Cancer – Draft Programme

Madrid, February 7-9, 2011

Organisers

Jorge Reis-Filho, The Breakthrough Breast Cancer Research Centre, London, UK
Lajos Pusztai, The University of Texas M. D. Anderson Cancer Center, Houston, USA
Joaquín Arribas, Vall d'Hebron Institute of Oncology, Barcelona, Spain
Josep Baselga, Vall d'Hebron Institute of Oncology, Barcelona, Spain
Miguel Ángel Piris, CNIO, Madrid, Spain

MONDAY, FEBRUARY 7th

9:00-9:15 **Welcome address: Miguel Angel Piris**

Session I: Relevance of cancer stem cells in breast cancer biology: A new beginning or a new hype?

Chair: Josep Baselga

9:15-9:50 **Gabriela Dontu**, King's College London, UK (*tbc*)
(40')

9:50-10:25 **Max Wicha**, University of Michigan Health System, Ann Arbor, USA (*tbc*)
(35')

10:25-11:00 **Robert Clarke**, Paterson Institute for Cancer Research, University of Manchester, UK
(35')

11:00-11:40 *Coffee break and poster session*
(40')

11:40-12:15 **Mathew Ellis**, Washington University Medical School, St. Louis, USA
(35')

12:15-12:50 **Salvatore Pece**, European Institute of Oncology, Milan, Italy
(35')
"Cancer stem cells and breast carcinogenesis: a new outlook on the molecular, biological and clinical heterogeneity of breast cancers"

12:50-14:20 *Lunch and poster session*
(1h 30')

Session II: Tumor stroma interactions and their prognostic and therapeutic implications

Chair: Jorge Reis-Filho

- 14:20-14:55 **Alex Toker**, Beth Israel Deaconess Medical Center, Harvard University, USA
(35')
- 14:55-15:30 **Achim Rody**, Goethe University, Frankfurt, Germany
(35') *"The distinct role of immune cells in molecular subtypes"*
- 15:30-16:05 **Zena Werb**, University of California, San Francisco, USA
(35') *"The regulation of tumor stroma during breast cancer progression"*
- 16:05-16:40 **Jean Paul Thiery**, Institute of Molecular and Cell Biology, Singapore
(35')
- 16:40-17:10 *Coffee break and poster session*
(30')
- 17:10-18:00 **Keynote lecture**
(50') **Metastasis biology**
Yosef Yarden, The Weizmann Institute of Science, Rehovot, Israel
"Roles for HER2 and EGFR in tumor stroma interactions and the opportunities they offer for therapeutic interventions"

TUESDAY, FEBRUARY 8th

Session III: Prognostic and predictive markers in the post-genomic era: One marker for all or different markers for each disease subset?

Chair: Lajos Pusztai

- 9:00-9:35 **Mitchell Dowset**, Royal Marsden Hospital, London, UK
(35') *"Integration of clinical and molecular markers in ER+ disease"*
- 9:35-10:10 *(tba)*
(35')
- 10:10-10:45 **Soonmyung Paik**, National Surgical Adjuvant Breast and Bowel Project
(35') Pittsburgh, USA
- 10:45-11:20 **Christos Sotiriou**, Jules Bordet Institute, Brussels, Belgium
(35')
- 11:20-11:55 *Group picture, coffee break and poster session*
(35')

Session IV: The next generation of drug targets and new treatment strategies to overcome drug resistance

Chair: Mitchell Dowset

11:55-12:25 **Charles Swanton**, Translational Cancer Therapeutics Laboratory, Cancer Research, London, UK
(30')
"Identification of Regulators of Drug Sensitivity and Chromosomal Instability in Cancer using Functional Genomics"

12:25-12:50 **Lajos Pusztai**, University of Texas, M.D. Anderson Cancer Center, Houston, USA
(25')

12:50-13:15 **Jorge Reis-Filho**, The Breakthrough Breast Cancer Research Centre, London, UK
(25')

13:15-13:40 **Joaquín Arribas**, Vall d'Hebron Institute of Oncology, Barcelona, Spain
(25')

13:40-15:20 ***Lunch and poster session***
(1h 40')

Short talks from selected abstracts

Chair: Joaquín Arribas

15:20-16:40 3 short talks from selected abstracts
(20')

16:00-16:40 ***Coffee break and poster session***
(40')

Chair: Jorge Reis-Filho

16:40-17:30 ***Keynote lecture***
(50')
Alan Ashworth, The Breakthrough Breast Cancer Research Centre, London, UK
"Synthetic lethal and high throughput genetic approaches to the development of new therapeutic approaches to cancer"

WEDNESDAY, FEBRUARY 9th

Session V: The next generation of tissue analysis tools: Promises and pitfalls of next generation sequencing

Chair: Miguel A. Piris

09:00-09:25 **Carlo Croce**, The Ohio State University, Columbus, USA
(25') **"miRNAs"**

09:25-09:50 **Michael R. Stratton**, Sanger Institute, London, UK
(25') **"Deep sequencing"**

09:50-10:15 **Emanuel Petricoin**, George Mason University, Fairfax, USA
(25') **"Development and Clinical Implementation of Functional Protein Pathway Activation Mapping of Breast Cancer for Personalized Therapy"**

10:15-10:45 *Coffee break and poster session*
(30')

Session VI: Innovative clinical trials

Chair: Christos Sotiriou

10:45-11:20 **Fabrice Andre**, Institute Gustave Roussy, Paris, France
(35') **"Molecular selection for biology-driven phase II trials: what is the best model?"**

11:20-11:55 **Miguel Ángel Quintela**, CNIO, Madrid, Spain
(35')

11:55-12:45 **Keynote lecture**
(50') **Josep Baselga**, Vall d'Hebron Institute of Oncology, Barcelona, Spain

12:45 Closing remarks and poster prize

Lajos Pusztai, University of Texas, M.D. Anderson Cancer Center, Houston, USA
Jorge Reis-Filho, The Breakthrough Breast Cancer Research Centre, London, UK

Note: Talks: 25 minutes / Short talk: 15 minutes / Keynote lectures: 40 minutes

Discussion: 10 minutes after each talk / 5 minutes after each short talk / 10 minutes after each keynote lecture